T-cell immunity generated by recombinant adenovirus vaccines.
Recombinant adenovirus vaccines show great promise for generating protective immunity against infectious agents and tumors. Our studies have identified several interesting biological features of the adenovirus vector that influence the T-cell response. Notably, we have demonstrated that following immunization with adenovirus vaccines, the transgene antigen remains available to the system for a longer period than would be expected, resulting in a T-cell population with a sustained effector phenotype. The implications of these observations with regards to the utility of adenovirus vaccines are discussed.
Yang
Teng Chih
TC
Center for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada. yangtt@mcmaster.ca
Millar
James B
JB
Grinshtein
Natalie
N
Bassett
Jennifer
J
Finn
Jonathan
J
Bramson
Jonathan L
JL
D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology*; D000818:Animals; D017951:Antigen Presentation; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology; D005822:Genetic Vectors; D006801:Humans; D014614:Vaccines, Synthetic / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology
D019496:Cancer Vaccines; D014614:Vaccines, Synthetic; D014765:Viral Vaccines